

Prostate Imaging Reporting and Data System score (PI-RADS) and Glutathione S-transferase P1 methylation status (GST-P1) in the diagnosis of prostate cancer patients with borderline PSA values

Marius Stan^{1,2}, Vladimir Bornarciuc², Andra I. Suceveanu³, Andreea C. Costea^{4*}, Adrian P. Suceveanu³, Laura Mazilu³, Ciprian Iorga^{1,2}, Tony Hangan³, Corneliu Tudor⁵, Dragos Epistatu⁶, Sergiu Chirila³, Viorel Gherghina³, Felix Voinea^{1,3}

¹EMERGENCY CLINICAL HOSPITAL OF CONSTANTA, DEPARTMENT OF UROLOGY, CONSTANTA, ROMANIA

²OVIDIUS UNIVERSITY OF CONSTANTA, DOCTORAL SCHOOL, CONSTANTA, ROMANIA

³OVIDIUS UNIVERSITY OF CONSTANTA, FACULTY OF MEDICINE, CONSTANTA, ROMANIA

⁴DIAPERUM CLINIC, CONSTANTA, ROMANIA

⁵EMERGENCY UNIVERSITY HOSPITAL BUCHAREST, FOURTH DEPARTMENT OF SURGERY, BUCHAREST, ROMANIA

⁶CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, DEPARTMENT OF RADIOLOGY, BUCHAREST, ROMANIA

ABSTRACT



Objectives. The objective of this study was to evaluate the potential use of Prostate Imaging – Reporting and Data System version 2 (PI-RADS) in combination with Glutathione S-transferase P1 (GST-P1) expression for an improved diagnosis of prostate cancer, in patients with inconclusive values of prostate-specific antigen (PSA). **Materials and Methods.** The study was conducted on 80 patients for whom PSA values were evaluated and were found to be inconclusive (4-10 ng/ml). These patients underwent imagistic evaluation (PI-RADS), followed by transurethral prostate biopsy, with the evaluation of GST-P1 expression and histopathological examination (for diagnosis confirmation). **Results.** By combining the results of PI-RADS and GST-P1 the capacity of the tests to correctly identify healthy subjects, with an area under curve of 0,832 (95% CI 0.732–0.907), with a sensitivity of 73,25% and a specificity of 77,78%. **Conclusions.** PI-RADS lesions and GST-P1 methylation testing when PSA levels are in a “grey zone”, provide a better specificity and sensitivity by comparison through single testing. Testing patients with inconclusive PSA levels allows for a more accurate diagnosis and less over-diagnosis by non-invasive procedures, such as repeated biopsies.

Category: Original Research Paper

Received: June 22, 2022

Accepted: August 10, 2022

Published: October 15, 2022

Keywords:

PI-RADS, GST-P1, prostate cancer, diagnosis, prostate-specific antigen

*Corresponding author:

Andreea Cristina Costea,

Diaperum Clinic of Constanta, Constanta, Romania, 900612

E-mail: acostea2021@gmail.com

Introduction

Neoplastic diseases play an important role in the mortality, combined representing the second biggest cause of death worldwide [1]. In addition to being a major cause of death, neoplastic diseases also have a major impact on quality of life. This is affected by the evolution of the disease, the treatment regimens that are required [2,3], or the difficulties related to the nutritional needs of cancer patients and the prevention of cachexia [4-6]. According to the data of World Health Organization, the most frequent cancers in male patients are prostate, colorectal and lung cancers and the incidence of these disease in on an increasing trend [7,8]. While one of the causes is aging of population, screening programs, based on less invasive

tests can lead to early diagnosis and increased chance for survival [8,9]. Prostate cancer, despite having one of the highest incidences of cancers in male population [10-12], also has a high five years survival rate when diagnosed in early stages [13]. Social disparities, with difficult access to medical services for patients within rural areas [14] or possible disabilities [15] influences the time to diagnosis and the evolution of the disease [16,17], especially in developing regions, an aspect that was also observed and analyzed in other pathologies [18,19]. Moreover, recently, several studies raised awareness upon neglecting cancer patients during the Covid-19 pandemic [20,21].

Current medical development introduced new diagnosis procedures, mainly through the usage of imaging methods, such as Prostate Imaging Reporting and Data

System version 2 (PI-RADS) [22] or, as in the case of other cancers [23], the development of tests that target genetic biomarkers [24-26]. There are multiple studies that evaluate the role of combining the PI-RADS with other diagnosis methods in order to increase the accuracy of prostate cancer diagnosis [27-29].

The results of all these efforts to clarify the status of the patient dramatically increases the survival rate through better and timely diagnosis [30] associated with modern systemic therapies, such as immunotherapies [31].

In this study we evaluate the potential use of PI-RADS in combination with Glutathione S-transferase P1 (GST-P1) expression in the diagnosis of prostate cancer patients with inconclusive (borderline) values of prostate specific antigen (PSA).

Materials and Methods

The study was an observational one, conducted on 80 consecutive patients (between January 2018 and January 2020) that presented either for control examination or due to lower urinary tract symptoms at the Urology clinic of County Hospital of Constanta. All those patients met the inclusion criteria of having an inconclusive PSA value between 4 and 10 ng/ml; PSA was evaluated by using the ECLIA method.

All patients included in the study underwent PI-RADS evaluation and prostate biopsy with histopathological examination and GST-P1 methylation testing. The histopathological examination was considered as being the golden standard for prostate cancer diagnosis. Possible results were prostate cancer or benign prostate hyperplasia.

We ran a binomial logistic regression procedure using the two variables (PI-RADS and GST-P1) as independent variables and the histopathological test as dichotomous dependent variable. The area under curve (AUC) was calculated and used to determine the performance of the variables in diagnosing prostate cancer, the best one being considered the one with the largest AUC.

Statistical analyses were conducted by using IBM SPSS Statistics version 26, a p value of less than 0.05 was considered statistically significant.

The study received ethical committee approval no 446/30.03.2018 of the Ethical Committee for clinical studies approval of the Emergency County Hospital Constanta. Procedures at all stages of the study were carried out in compliance with the principles of the Declaration of Helsinki. Informed consent forms were received from all participants before the enrolment in the study group.

Results

Patient characteristics are summarized in Table 1. The average age of the patients was 68 years, with an average value of PSA level of 7.1 ng/ml. More than half of the

patients presented GST-P1 methylation (42 of 80) and for PI-RADS score, no patient had a score of 5, one patient had a score of 1 and most of the patient (50%) presented with an intermediate score [3]. Around two thirds of the patients were histopathologically diagnosed with prostate cancer.

Table 1. General characteristics of the patients included in the study group

Characteristics	Values
Patients (n=80)	
Age (mean±sd, years)	68.0±9.16
PSA (mean±sd, ng/ml)	7.1±1.82
GST-P1 Methylation	
Negative (n, %)	38 (47.5%)
Positive (n, %)	42 (52.5%)
PI-RADS 2	
1 - Very Low (n, %)	1 (1.3%)
2 - Low (n, %)	21 (26.3%)
3 - Intermediate (n, %)	40 (50%)
4 - High (n, %)	18 (22.5%)
5 - Very High (n, %)	0 (0%)
Prostate Cancer	
Positive (n, %)	53 (66.3%)
Negative (n, %)	27 (33.8%)
Footnote. PSA: prostate-specific antigen, GST-P1: Glutathione-S-transferase gene P1, PI-RADS: Prostate Imaging Reporting and Data System scoring system v.2	

The sensitivity and specificity of PI-RADS, for diagnosing prostate cancer in patients with borderline values of PSA, when the cut-off value was considered to be 4, were 96.3% (95% CI 81.0% - 99.9%) respectively 32.08% (95% CI 19.9% - 46.3%). Detailed values are in Table 2 for different cut-off points.

Table 2. Diagnostic accuracy of PI-RADS in the study group

Criterion	Sensitivity	95% CI	Specificity	95% CI
≥1	100.00	93.3 - 100.0	0.00	0.0 - 12.8
>1	100.00	93.3 - 100.0	3.70	0.09 - 19.0
>2	83.02	70.2 - 91.9	48.15	28.7 - 68.1
>3	32.08	19.9 - 46.3	96.30	81.0 - 99.9
>4	0.00	0.0 - 6.7	100.00	87.2 - 100.0

We further ran a binomial regression using as predictors the PI-RADS score and GST-P1 methylation. The logistic regression model was statistically significant $\chi^2(2) = 27.82$, $p < 0.001$. The model explained 40.7% (Nagelkerke R square) of the variance in prostate cancer diagnosis and correctly classified 78.8% of the cases. Sensitivity was 79.25%, specificity was 77.78%, positive predictive value 87.5% and negative predictive value was 65.62%. Of the two predictor variables both were statistically significant (Table 3). Men for whom the GST-P1 was methylated had 7.92 higher odds of having prostate cancer. Increasing value of the PI-RADS score was

associated with an increased likelihood of having prostate cancer, each grade having 3.01 times higher odds for prostate cancer compared to the previous score.

Table 3. Logistic regression predicting likelihood of prostate cancer based on GST-P1 methylation and PI-RADS score

	B	S.E.	Wald	df	p	Odds Ratio	95% C.I. for Odds Ratio	
							Lower	Upper
GST-P1 Methylation (1)	2.07	.61	11.66	1	.001	7.92	2.41	25.95
PI-RADS Stabilization	1.13	.43	6.84	1	.009	3.01	1.33	7.23
Constant	-3.43	1.25	7.46	1	.006	.032		

When combined, the predictive value of the combination of PI-RADS and GST-P1 (AUC 0.832, 95% CI 0.732 – 0.907) was superior in a statistically significant way to each of the two evaluations alone. For GST-P1 the AUC was 0.756, (95% CI 0.644 – 0.869, $p=0.015$), and for PI-RADS the AUC was 0.727 (95% CI 0.616 – 0.820, $p=0.014$).




Figure 1. Comparison of ROC for Combined PI-RADS2 + GST-P1 versus alone

Discussion

A growing number of novel biomarkers are currently under investigation. Such markers include urinary biomarkers, serology-based markers or pathological tissue assessments of molecular and genetic markers [32]. Several cytokines were investigated for the possible correlation with prostate cancer, such as IL-1 α , IL-1 β , IL-6, and TNF- α . The incriminated mechanism is thought to be the high fat diet that simulate a pro-inflammatory state [33]. IL-6 type cytokines belong to the long-chain 4 α -helix hematopoietic cytokine family, and plays multiple biological roles in inflammation, hemostasis and immune response [34]. Serum levels of IL-6 correlate with prostate tumor burden and patient morbidity. The prostate tissue itself appears to be a source of IL-6 and its receptor [35].

Other studies found that cytokines such as IL-1 and IL-3, may have a role in angiogenesis [36].

In this study, the first to assess the combined role of PI-RADS and GST-P1 in the diagnosis of prostate cancer, we observed that, for patients with borderline PSA values, both GST-P1 and PI-RADS had good diagnostic performance for detecting prostate cancer, and by using the combined results, the capacity of the test to discriminate prostate cancer patients increases.

A major role in the survival of cancer patients is the capacity of the medical system to diagnose them as early as possible. For prostate cancer, prostatic specific antigen (PSA) and digital rectal examination (DRE) are widely and well-known methods used for the diagnosis of prostate cancer [37], easy to perform and generally cheap. Using the DRE as a predictor of prostate cancer is useful, in symptomatic patients [38], and abnormal test being an indicator of cancer risk, raising the concern and determining the referral of the patients to secondary level medical care for diagnosis purposes.

At the same time, PSA can have a significant number of irrelevant results, with low sensitivity [39] when 4ng/ml limit is used, and a significant number of tests within the borderline values. These cases require further investigation for clarification of the diagnosis [40,41], thus current research suggests PSA testing should be carefully evaluated and discussed with the patients [42] in order to maximize the benefits and limit the harm this procedure can have.

In the current study, we observed that PI-RADS values of at least 4 ensured a very high specificity for prostate cancer diagnosis, of 96.3%. Such a results offers very good perspectives in using it for ruling out healthy patients with borderline PSA values. These results are similar to the ones reported in the literature when PI-RADS was used in diagnosing prostate cancer [43,44].

When combined with GST-P1 testing, the precision of the imagistic method of diagnosing prostate cancer increased in a statistically significant way ($p=0,014$).

The results within this study suggest that by combining different methods of evaluating the patients, the success rate of a correct and timely diagnosis improves significantly.

Conclusions

PI-RADS lesions and GST-P1 methylation testing when PSA levels are in a “grey-zone”, provide a better specificity and sensitivity by comparison to single testing. Testing patients with inconclusive PSA-levels, allows a more accurate diagnosing and less over diagnosing by non-invasive procedures, such as repeated biopsies. These results further sustain the potential of improved diagnostics by interleaved imaging studies and prostate biomarkers.

Highlights

- ✓ Early diagnosis in prostate cancer is extremely important for achieving a high 5 years survival rate.
- ✓ The use of GST-P1 and PI-RADS tests in patients with inconclusive PSA-levels, allows less over-diagnosing by non-invasive procedures, such as repeated biopsies.

Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

Compliance with ethical standards

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

References

1. Lee AJ, Wnorowski A, Ye N, Xu L, Naslund M, Wood BJ, Merino MJ, Turkbey B, Choyke PL, Pinto PA, Siddiqui MM. Validation of an MRI-based prostate cancer prebiopsy Gleason score predictive nomogram. *Curr Urol.* 2022 Mar;16(1):38-43. doi: 10.1097/CU9.0000000000000069
2. Mazilu L, Stanculeanu DL, Gheorghe AD, Voinea F, Suceveanu AP, Pituru S, et al. Incidence of chemotherapy-induced peripheral neuropathy in cancer patients in clinical practice. *Farmacia.* 2019;67(3): 472-6. doi: 10.31925/farmacia.2019.3.14
3. Murillo-Zamora E, Mendoza-Cano O, Ríos-Silva M, Sánchez-Piña RA, Higareda-Almaraz MA, Higareda-Almaraz E, Lugo-Radillo A. Disability-Adjusted Life Years for Cancer in 2010-2014: A Regional Approach in Mexico. *Int J Environ Res Public Health.* 2018 Apr 26;15(5):864. doi: 10.3390/ijerph15050864
4. Ciuhu A.N., Pantea-Stoian, AM., Nitipir, C., et al. (2017). Assessment of cachexia in cancer patients with advanced disease. Book Series, International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications, pp: 139-147.
5. Savlovschi C, Serban D, Andreescu C, Dascalu A, Pantu H. Economic analysis of medical management applied for left colostomy. *Chirurgia (Bucur).* 2013 Sep-Oct;108(5):666-9.
6. Nitipir C, Diaconu CC, Orlov C, Pantea-Stoian A, Hainarosie R, et al. The Necessity of Nutritional Intervention in the Oncological Patient. What is the Evidence?, PROCEEDINGS OF THE 35th Balkan Medical Week (Athens, Greece, 25-27 September 2018) 2018; pp.133-137.
7. Netto GJ, Amin MB, Compérat EM, Gill AJ, Hartmann A, Moch H, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Berney DM. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. *Eur Urol.* 2022 Oct 4:S0302-2838(22)02644-6. doi: 10.1016/j.eururo.2022.09.015
8. Savlovschi C, Serban D, Trotea T, Borcan R, Dumitrescu D. Post-surgery morbidity and mortality in colorectal cancer in elderly subjects. *Chirurgia (Bucur).* 2013 Mar-Apr;108(2):177-9.
9. Şavlovschi C, Comandaşu M, Şerban D. Specifics of diagnosis and treatment in synchronous colorectal cancers (SCC). *Chirurgia (Bucur).* 2013 Jan-Feb; 108(1):43-5.
10. Chirilă S, Rugină S, Broască V. Neoplastic Diseases Incidence in Constanta County During 2007 – 2012. *ARS Medica Tomitana.* 2015;20(4): 211-214. doi: 10.1515/arism-2015-0008
11. Boyle P, Maisonneuve P, Napalkov P. Incidence of prostate cancer will double by the year 2030: the argument for. *Eur Urol.* 1996;29 Suppl 2:3-9. doi: 10.1159/000473828
12. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708
13. Rasouli MA, Moradi G, Zareie B, Sofimajidpour H, Tozandehjani S, Zafari H, Gholami F, Shahsavari S, Hassani P, Mohammadian M. Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018). *BMC Cancer.* 2021 Dec 8;21(1):1314. doi: 10.1186/s12885-021-09078-8
14. Stolzenbach LF, Deuker M, Collà-Ruvolo C, Nocera L, Tian Z, Maurer T, Tilki D, Briganti A, Saad F, Mirone V, Chun FKH, Graefen M, Karakiewicz PI. Differences between rural and urban prostate cancer patients. *World J Urol.* 2021 Jul;39(7):2507-2514. doi: 10.1007/s00345-020-03483-7
15. Shin DW, Park J, Yeob KE, Yoon SJ, Jang SN, Kim SY, Park JH, Park JH, Kawachi I. Disparities in prostate cancer diagnosis, treatment, and survival among men with disabilities: Retrospective cohort study in South Korea. *Disabil Health J.* 2021 Oct; 14(4):101125. doi: 10.1016/j.dhjo.2021.101125
16. Song QL, Qian Y, Min X, Wang X, et al. Urban-Rural Differences in Clinical Characteristics of Prostate Cancer at Initial Diagnosis: A Single-Center Observational Study in Anhui Province, China. *Front Oncol.* 2021 Aug 3;11:704645. doi: 10.3389/fonc.2021.704645
17. Bhatia S, Landier W, Paskett ED, Peters KB, Merrill JK, Phillips J, Osarogiagbon RU. Rural-Urban Disparities in Cancer Outcomes: Opportunities for Future Research. *J Natl Cancer Inst.* 2022 Jul 11; 114(7):940-952. doi: 10.1093/jnci/djac030

18. Stefanopol IA, Baroiu L, Chirila S, Miulescu M, Anghel L, Nechita L, Dinu CA, Stefanescu V, Bobeica C, Nechifor A, Tatu AL. The Influence of Living in Rural Areas on the Evolution and Management of Pediatric Ovarian Cystic Lesions: A Retrospective Study on a Cohort from South Eastern Romania. *Int J Gen Med*. 2022 May 27;15:5273-5284. doi: 10.2147/IJGM.S368202
19. Foley GR, Blizzard CL, Stokes B, Skala M, Redwig F, Dickinson JL, Fitzgerald LM. Urban-rural prostate cancer disparities in a regional state of Australia. *Sci Rep*. 2022 Feb 22;12(1):3022. doi: 10.1038/s41598-022-06958-2.
20. Serban D, Socea B, Badiu CD, Tudor C, Balasescu SA, Dumitrescu D, Trotea AM, Spataru RI, Vancea G, Dascalu AM, Tanasescu C. Acute surgical abdomen during the COVID-19 pandemic: Clinical and therapeutic challenges. *Exp Ther Med*. 2021 May; 21(5):519. doi: 10.3892/etm.2021.9950
21. Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, Garrett A, Gronthoud F, Nicol DL, Jhanji S, Boyce SA, Williams M, Riboli E, Muller DC, Kipps E, Larkin J, Navani N, Swanton C, Lyratzopoulos G, McFerran E, Lawler M, Houlston R, Turnbull C. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. *Lancet Oncol*. 2020 Aug;21(8):1035-1044. doi: 10.1016/S1470-2045(20)30392-2
22. Schwen ZR, Mamawala M, Tosoian JJ, Druskin SC, Ross AE, Sokoll LJ, Epstein JI, Carter HB, Gorin MA, Pavlovich CP. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance. *BJU Int*. 2020 Sep;126(3):373-378. doi: 10.1111/bju.15101
23. Suceveanu AI, Micu IS, Baltatescu GI, Petcu LC, Dobrin N, Brinzan C, Nitipir C, Mazilu L, Botea F, Herlea V, Voinea F, Suceveanu AP. Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area. *Exp Ther Med*. 2021 Mar;21(3):284. doi: 10.3892/etm.2021.9715
24. Santric V, Djokic M, Suvakov S, Pljesa-Ercegovac M, Nikitovic M, Radic T, Acimovic M, Stankovic V, Bumbasirevic U, Milojevic B, Babic U, Dzamic Z, Simic T, Dragicevic D, Savic-Radojevic A. GSTP1 rs1138272 Polymorphism Affects Prostate Cancer Risk. *Medicina (Kaunas)*. 2020 Mar 13;56(3):128. doi: 10.3390/medicina56030128
25. García-Cruz E, Otero JR, Ineva PA, Pérez LMM, Elías LP, Asensio AA. Robot-assisted aquablation for resection of benign prostatic hyperplasia: A series of cases. *J Clin Invest Surg*. 2020;5(1):18-23. doi: 10.25083/2559.5555/5.1/18.23
26. Zhou X, Jiao D, Dou M, Chen J, Li Z, Li Y, Liu J, Han X. Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis. *J Cancer Res Clin Oncol*. 2019 Aug;145(8):1939-1948. doi: 10.1007/s00432-019-02962-8
27. Polanec SH, Bickel H, Wengert GJ, Arnoldner M, Clauser P, Susani M, Shariat SF, Pinker K, Helbich TH, Baltzer PAT. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI? *Clin Radiol*. 2020 Feb;75(2):157.e1-157.e7. doi: 10.1016/j.crad.2019.09.139
28. Tafuri A, Iwata A, Shakir A, Iwata T, Gupta C, et al. Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS™ 5 and Prostate Specific Antigen Density Greater than 15. *J Urol*. 2021 Aug;206(2):289-297. doi: 10.1097/JU.0000000000001766
29. Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. *J Urol*. 2019 Feb;201(2):300-307. doi: 10.1016/j.juro.2018.08.047
30. Seraphin TP, Joko-Fru WY, Manraj SS, Chokunonga E, Somdya NIM, et al. Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study. *Cancer Causes Control*. 2021 Sep;32(9):1001-1019. doi: 10.1007/s10552-021-01453-x
31. Voinea F, Mazilu L, Micu IS, Suceveanu AP, Iliescu M, Dumitru A, Constantin VD, Paunica I, Suceveanu AI. Modern approaches for antiandrogen-resistant prostate cancer therapy. *J Mind Med Sci*. 2021;8(1):71-5. doi: 10.22543/7674.81.P7175
32. McGrath S, Christidis D, Perera M, Hong SK, Manning T, Vela I, Lawrentschuk N. Prostate cancer biomarkers: Are we hitting the mark? *Prostate Int*. 2016 Dec; 4(4):130-135. doi: 10.1016/j.pnrl.2016.07.002
33. Xu H, Hu MB, Bai PD, Zhu WH, Liu SH, Hou JY, Xiong ZQ, Ding Q, Jiang HW. Proinflammatory cytokines in prostate cancer development and progression promoted by high-fat diet. *Biomed Res Int*. 2015;2015:249741. doi: 10.1155/2015/249741
34. Brănescu C, Serban D, Dascălu AM, Oprescu SM, Savlovski C. Interleukin 6 and lipopolysaccharide binding protein - markers of inflammation in acute appendicitis. *Chirurgia (Bucur)*. 2013 Mar-Apr; 108(2):206-14.
35. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. *Cytokine Growth Factor Rev*. 2001 Mar;12(1):33-40. doi: 10.1016/s1359-6101(00)00021-6

36. Serban D, Papanas N, Dascalu AM, Stana D, Nicolae VA, Vancea G, Badiu CD, Tanasescu D, Tudor C, Balasescu SA, Pantea-Stoian A. Diabetic Retinopathy in Patients With Diabetic Foot Ulcer: A Systematic Review. *Int J Low Extrem Wounds*. 2021 Jun;20(2):98-103. doi: 10.1177/1534734620982237
37. Munteanu VC, Munteanu RA, Gulei D, Schitcu VH, Petrut B, Berindan Neagoe I, Achimas Cadariu P, Coman I. PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer. *Diagnostics (Basel)*. 2020 Oct 10; 10(10):806. doi: 10.3390/diagnostics10100806
38. Jones D, Friend C, Dreher A, Allgar V, Macleod U. The diagnostic test accuracy of rectal examination for prostate cancer diagnosis in symptomatic patients: a systematic review. *BMC Fam Pract*. 2018 Jun 2; 19(1):79. doi: 10.1186/s12875-018-0765-y
39. Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. *Arch Ital Urol Androl*. 2006 Dec;78(4):125-9.
40. Ross T, Ahmed K, Raison N, Challacombe B, Dasgupta P. Clarifying the PSA grey zone: The management of patients with a borderline PSA. *Int J Clin Pract*. 2016 Nov;70(11):950-959. doi: 10.1111/ijcp.12883
41. Ceausu Z, Socea B, Dimitriu MCT, Predescu D, Constantin VD, Bacalbaşa N, Cîrstoveanu C, Costache M, Ceausu M. Dormant cardiac stem cells: A promising tool in cardiac regeneration. *Exp Ther Med*. 2020 Oct;20(4):3452-3457. doi: 10.3892/etm.2020.9015
42. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. *BMJ*. 2018 Sep 5; 362:k3519. doi: 10.1136/bmj.k3519
43. Park KJ, Choi SH, Kim MH, et al. Performance of Prostate Imaging Reporting and Data System Version 2.1 for Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. *J Magn Reson Imaging*. 2021 Jul;54(1):103-112. doi: 10.1002/jmri.27546
44. Kubihal V, Kundra V, Lanka V, Sharma S, Das P, Nayyar R, Das CJ. Prospective evaluation of PI-RADS v2 and quantitative MRI for clinically significant prostate cancer detection in Indian men - East meets West. *Arab J Urol*. 2022 May 15;20(3):126-136. doi: 10.1080/2090598X.2022.2072141